Human drug hepatotoxicity: a contemporary clinical perspective

Background: Drug-induced liver injury (DILI) constitutes a significant medical challenge. The rising number of marketed drugs, aging population and polypharmacy make it imperative to understand the clinical presentation of DILI and the processes used in the assessment of causality and early detection. Objective: This article reviews the current clinical understanding of DILI including presentation patterns, causality assessment, risk factor ascertainment and early detection strategies including liver test monitoring. Significant initiatives such as the Drug-Induced Liver Injury Network (DILIN) are also discussed. Methods: A narrative review of clinical studies of DILI, with emphasis on clinical features, causality and surveillance. Conclusion: DILI remains a serious challenge in contemporary clinical practice. Further research and collaboration in the areas of epidemiology, causality and early detection are required to enhance the diagnosis and management of DILI.

[1]  R. Andrade,et al.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. , 2007, World Journal of Gastroenterology.

[2]  Paul B Watkins,et al.  Idiosyncratic Liver Injury: Challenges and Approaches , 2005, Toxicologic pathology.

[3]  C. Day.  Nash-related liver failure: one hit too many? , 2002, American Journal of Gastroenterology.

[4]  T. Schiano,et al.  Review article: drug hepatotoxicity , 2007, Alimentary pharmacology & therapeutics.

[5]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[6]  W. Ray,et al.  Population-based studies of adverse drug effects. , 2003, The New England journal of medicine.

[7]  P. Watkins.  Drug-Induced Liver Injury Network , 2008, The American Journal of Gastroenterology.

[8]  William M. Lee,et al.  Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. , 2006, Gastroenterology.

[9]  J. Reichen,et al.  Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. , 2007, Journal of hepatology.

[10]  A. Issa.  Clinical applications of pharmacogenomics to adverse drug reactions , 2008, Expert review of clinical pharmacology.

[11]  R. Andrade,et al.  Comparison of two clinical scales for causality assessment in hepatotoxicity , 2001, Hepatology.

[12]  R. Andrade,et al.  Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury , 2008, Hepatology.

[13]  J. Senior,et al.  Troglitazone-induced liver failure: a case study. , 2003, The American journal of medicine.

[14]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[15]  C. Degott,et al.  Drug‐induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia , 1992, Hepatology.

[16]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[17]  R. Victorino,et al.  Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.

[18]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.

[19]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[20]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[21]  W. Bailey,et al.  Risk factors for isoniazid (NIH)-induced liver dysfunction. , 1981, Journal of clinical gastroenterology.

[22]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[23]  D. Snider,et al.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. , 1978, The American review of respiratory disease.

[24]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[25]  S. Buskin,et al.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. , 1999, JAMA.

[26]  P. Rosenthal,et al.  Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. , 2006, The Journal of pediatrics.

[27]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[28]  R. Fontana,et al.  Drug-Induced Liver Injury Network (DILIN) Prospective Study , 2009, Drug safety.

[29]  M. Yoshioka,et al.  Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido , 2003, Annals of Internal Medicine.

[30]  R. Fontana.  Acute liver failure including acetaminophen overdose. , 2008, The Medical clinics of North America.

[31]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[32]  C. Quereda,et al.  Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[34]  C. Grönhagen-Riska,et al.  Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. , 2015, The American review of respiratory disease.

[35]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[36]  P. Watkins,et al.  Liver transplantation for acute liver failure from drug induced liver injury in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[37]  Paul B Watkins,et al.  Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.

[38]  H. Bonkovsky.  Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). , 2006, Annals of internal medicine.

[39]  R. Fontana,et al.  Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury , 2008, Hepatology.

[40]  What is idiosyncratic hepatotoxicity? What is it not? , 2008, Hepatology.

[41]  R. Victorino,et al.  Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury , 1997, Gut.

[42]  D. Mendrick,et al.  Biomarkers of drug-induced adverse events , 2008, Expert review of clinical pharmacology.

[43]  H. El‐Serag,et al.  Diabetes increases the risk of acute hepatic failure. , 2002, Gastroenterology.

[44]  D J Graham,et al.  Liver enzyme monitoring in patients treated with troglitazone. , 2001, JAMA.

[45]  William M. Lee,et al.  Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.

[46]  A. Fourrier-Réglat,et al.  Agreement of expert judgment in causality assessment of adverse drug reactions , 2005, European Journal of Clinical Pharmacology.

[47]  James H. Lewis,et al.  Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. , 2007, Clinics in liver disease.

[48]  A. Albanese,et al.  Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. , 1998, American journal of respiratory and critical care medicine.

[49]  D. Larrey.  Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver , 2002, Seminars in liver disease.

[50]  B. Davis,et al.  Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project , 2002, Circulation.

[51]  William M. Lee,et al.  Telithromycin‐associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases , 2009, Hepatology.

[52]  M. Rawlins,et al.  Accuracy of hepatic adverse drug reaction reporting in one English health region , 1999, BMJ.

[53]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[54]  D. Hochstrasser,et al.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis , 2006, European Journal of Clinical Pharmacology.

[55]  G. Tarantino,et al.  A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver disease , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[56]  M. Madariaga,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[57]  Chandan Saha,et al.  Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.

[58]  J. Hoofnagle,et al.  Drug‐induced liver injury network (DILIN) , 2004, Hepatology.

[59]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[60]  P. Beaune,et al.  Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. , 1996, Molecular pharmacology.

[61]  E. Elinav,et al.  Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. , 2007, Journal of hepatology.

[62]  V. Desmet.  Vanishing bile duct syndrome in drug-induced liver disease. , 1997, Journal of hepatology.

[63]  Chih‐Yen Chen,et al.  Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. , 2007, Journal of hepatology.

[64]  N. Goldschlager,et al.  Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. , 2000, Archives of internal medicine.

[65]  C. Codina,et al.  The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. , 2001, European journal of clinical pharmacology.

[66]  K. Ishak,et al.  Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients , 1989, Hepatology.

[67]  M. Pirmohamed,et al.  Adverse drug reactions and pharmacogenomics: recent advances. , 2008, Personalized medicine.

[68]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[69]  Michael P Holt,et al.  Drug-induced liver injury. , 2010, Handbook of experimental pharmacology.

[70]  M. Pirmohamed,et al.  Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor , 2008 .

[71]  Mph Dr. Syed Rizwanuddin Ahmad MD.  Adverse drug event monitoring at the food and drug administration , 2007, Journal of General Internal Medicine.

[72]  K. Reddy,et al.  Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. , 2004, Journal of hepatology.

[73]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[74]  K. Tolman.  The liver and lovastatin. , 2002, The American journal of cardiology.

[75]  S. Shapiro,et al.  Adverse drug reactions in children leading to hospital admission. , 1988, Pediatrics.

[76]  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.

[77]  T. Self,et al.  Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. , 2005, Chest.